Key Points
- Director Dr. Arun Menawat bought 20,000 shares of Profound Medical on March 20 at an average price of C$6.96, raising his stake to 658,660 shares (a 3.13% increase) valued at about C$4.58M.
- Profound Medical trades near C$8.88 with a market cap of C$322.3M, shows negative profitability metrics (recent quarter EPS C$0.37 but ROE -85.73% and net margin -248.45%), and analysts forecast about -1.90 EPS for the current fiscal year.
-logo-1200x675.PNG?v=20210211152252)
Profound Medical Corp. (TSE:PRN - Get Free Report) Director Dr. Arun Menawat acquired 20,000 shares of the firm's stock in a transaction dated Friday, March 20th. The shares were purchased at an average cost of C$6.96 per share, with a total value of C$139,200.00. Following the completion of the transaction, the director owned 658,660 shares in the company, valued at approximately C$4,584,273.60. The trade was a 3.13% increase in their position.
Profound Medical Stock Performance
TSE:PRN opened at C$8.88 on Friday. The firm has a market capitalization of C$322.29 million, a PE ratio of -6.30 and a beta of 1.10. The business's fifty day moving average price is C$8.89 and its 200 day moving average price is C$9.01. The company has a debt-to-equity ratio of 7.09, a current ratio of 12.52 and a quick ratio of 14.98. Profound Medical Corp. has a 12 month low of C$5.23 and a 12 month high of C$12.40.
Profound Medical (TSE:PRN - Get Free Report) last posted its quarterly earnings results on Thursday, March 5th. The company reported C$0.37 earnings per share for the quarter. The company had revenue of C$8.00 million for the quarter. Profound Medical had a negative return on equity of 85.73% and a negative net margin of 248.45%. On average, sell-side analysts anticipate that Profound Medical Corp. will post -1.9000001 earnings per share for the current fiscal year.
About Profound Medical
(
Get Free Report)
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
